Compare Devon Energy Corp (DVN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Devon Energy Corp trades at $50.23 (market cap $55.23B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Devon Energy Corp is far larger — about 11.3× Travere Therapeutics Inc. Common Stock's market cap, and Devon Energy Corp pays a 2.55% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| DVN | TVTX | |
|---|---|---|
Market Cap | $55.23B | $4.88B |
Volume | 10,032,111 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $52.07 | $67.52 |
52-Week Low | $31.74 | $26.79 |
Typical Hold Time | 136 Days | 0 Days |
Enterprise Value | $65.97B | $5.01B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $50.21, up 2.55% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $62.44 implying significant upside. Recent financials show revenue of $17.19B in 2025 with a net income margin of 16.67%, while valuation ratios like a P/E of 10.92 appear attractive. Activist investor Toms Capital is urging strategic review, including a potential sale, as highlighted in recent news (CNBC, 2026-09-23).
The outlook is positive given strong analyst support (72% buy ratings) and projected 2026 revenue growth to $19.7B. Key risks include oil price volatility and execution of potential asset sales. The stock presents a value opportunity with upside to price targets, though dependent on commodity markets and corporate strategy developments.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
